NetScientific portfolio company, Glycotest Inc., appoints world leading medical advisory board chaired by David Chernoff, M.D.
London, UK – 6 January 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints a medical advisory board of leading liver experts to advise on the development of Glycotest’s diagnostic tests for liver related diseases.
Scott Friedman, MD and Douglas Dieterich, MD have been appointed to the advisory board alongside the chair, David Chernoff, MD.
Glycotest is a molecular diagnostics company commercialising clinical laboratory testing services to reduce mortality and increase survival for patients at risk from liver cancers and fibrosis-cirrhosis. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay methodology that exploit novel sugar-based disease signal chemistry.
David Chernoff, MD is a molecular diagnostics industry veteran who has played pivotal roles in the launch of multiple products such Vectra DA (Crescendo Bioscience), AlloMap (CareDx) and HIV, HBV and HCV bDNA tests (Chiron Diagnostics). He brings both senior clinical leadership experience and a key commercial perspective to his role as chair of Glycotest’s Medical Advisory Board. Dr. Chernoff has served as Chief Medical Officer at multiple entrepreneurial molecular diagnostics companies, most recently Crescendo Bioscience, and previously was Vice President of Corporate Technology at Elan Pharmaceuticals and Medical Director at Chiron Diagnostics. Dr. Chernoff holds an MD degree from New York University and completed his medical training at the University of California, San Francisco.
Scott Friedman, MD is Chief of the Division of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai, New York and was President of the American Association for the Study of Liver Diseases (AASLD) in 2009. Dr. Friedman is one of the foremost leaders in the field of liver fibrosis, having been the first to isolate and characterise the causative cell type. He contributes a wealth of experience with emerging diagnostic and therapeutic approaches in serious liver disease. Dr. Friedman received his MD degree from Mount Sinai and completed his training at Beth Israel Hospital, Boston and the University of California, San Francisco.
Douglas Dieterich, MD is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York with appointments in the Divisions of Liver Diseases, Gastroenterology and Infectious Diseases, and is the newly appointed Director for the Institute for Liver Medicine at the Mount Sinai Health System. Chronic hepatitis B and C are key focal areas of Dr. Dieterich’s clinical research and he has authored many publications on viral hepatitis and AIDS-related infections of the liver. His extensive clinical practice experience in serious liver disease will be a vital resource for Glycotest. Dr. Dieterich’s MD degree is from New York University School of Medicine and he completed his medical training at Bellevue Hospital Center in New York.
Commenting on the appointments, NetScientific’s Chief Executive Officer, Francois R. Martelet said: “Dr. Chernoff’s appointment as Chairman of Glycotest’s Medical Advisory Board and the appointments of Dr Scott Friedman and Dr Douglas Dieterich complements our strategy of advancing the development and commercialisation of these novel tests in the US market. We look forward to drawing upon the team’s extensive experience within the specific liver disease market that we are initially focusing on.”
– Ends –
François R. Martelet, M.D., CEO
Peter Thoms, CFO
Tel: +44 (0)20 3514 1800
Investec (NOMAD and broker)
Gary Clarence / Daniel Adams
Tel: +44 (0)20 7597 4000
Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest
Tel: +44 (0)20 7457 2020 Email: firstname.lastname@example.org
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment.
For more information, please visit the website at www.netscientific.net.
Glycotest is a molecular diagnostics company commercialising novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Glycotest provides financial compensation to the members of the Medical Advisory Board for their service. www.glycotest.com